This Undiscovered ultra low float stock could be a Once in a Lifetime Opportunity please do your own dd and realize the MEGA Potential here .

SteadyMed (STDY) is a undiscovered stock which is close to NDA & EMA filing (expected in 4Q 2016) for their Big Orphan Drug called Trevyent? for the treatment of pulmonary arterial hypertension (PAH) . SteadyMed is trading almost at Cash Level and lots of Insider & Institutions paid over $8 per Share now trading at just $2.50 more Infos below .I think this Stock really has MEGA upside Potential .GL

SteadyMed (Nasdaq: STDY)


Market Cap: $34.9 Million
Cash: $31.8 Million
Price: $2.57

Shares Out : 13.58 Million

Insiders & Institutions holding 10.8 Million Shares


Presentation Februar 2016

http://phx.corporate-ir.net/External...R5cGU9MQ==&t=1


Trevyent? for pulmonary arterial hypertension (PAH)

? Combination of treprostinil and our PatchPump? platform technology
- Goal - to overcome the limitations of market leader Remodulin? (treprostinil)
- Expected NDA filing in Q3 2016
? Potential high revenue, high margin ~$180,000 per patient per year
? Potential >$4 Billion addressable market opportunity in U.S.


Bio-waiver confirmed ? No clinical studies required for approval
? 505(b)(2) NDA in the U.S.
? Hybrid 10(3) Application in the E.U. - granted Centralized Review by EMA
NDA submission anticipated Q3 2016 and E.U. MAA H2 2016
Remodulin safety and efficacy data to be included in Trevyent prescribing
information
Example of FDA product approvals through bio-waiver
? Parenteral epoprostenol reformulation (Veletri?, Actelion) for PAH

Pipeline of two At-Home Patient Analgesia (AHPA) product candidates

? SMT ? 201 (Ketorolac). Anticipate pivotal / registration trial H2 2016

? SMT ? 301 (Bupivacaine.) Formulation development and technical feasibility ongoing

STDY Insider Transactions | SteadyMed Ltd. Stock - Yahoo! Finance

Mar 25, 2015 STARK BRIAN JAYDirector 1,288,112 Indirect Acquisition (Non Open Market) at $8.50 per share. 10,948,952
Mar 25, 2015 FLYNN JAMES EBeneficial Owner (10% or more) 737,555 Indirect Purchase at $8.50 per share. 6,269,217
Mar 25, 2015 GINOR RONDirector 1,075,102 Indirect Acquisition (Non Open Market) at $8.50 per share. 9,138,367
Mar 25, 2015 BANK KEITHDirector 2,294,283 Indirect Acquisition (Non Open Market) at $8.50 per share. 19,501,405